7 results about "Toll-like receptor" patented technology

The present disclosure relates generally to toll like receptor modulator compounds, such as diamino pyrido[3,2 D] pyrimidine compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR-8), and methods of making and using them.

Disclosed is a cancer vaccine that contains dendritic cells. The dendritic cells are prepared by: culturing immature dendritic cells to maturation; co-culturing the matured dendritic cells with attenuated cancer cells, Mannan – BAM (Mannan, a yeast-derived polysaccharide, and BAM, a Biocompatible Anchor for Cell Membrane), and TLR (Toll like receptor) agonists; and optionally sorting the dendritic cells from the co-cultured attenuated cancer cells.

The invention belongs to the technical field of animal immune regulation, and particularly relates to a function regulator based on a sheep neutrophil release extracellular trapping net and application of the function regulator. The functional regulator is prepared from the following components: a Jacquard trophozoite, DPI (Diisopropylamine), U0126, SB202190, C29 and TLR-IN-C34 (Toll Like Receptor-IN-C34). Through multi-channel cooperative regulation and control, an agonist giardia trophozoite and channel inhibitors such as NADPH oxidase, MAPK and TLR are integrated, and accurate dynamic regulation of NETs release is achieved; livestock medicine pertinence: the sheep neutrophile granulocytes are specially designed, and the research blank of NETs regulation and control of economic animals is filled up; the application scene is expanded, and the method has the bidirectional treatment potential of infectious diseases and autoimmune diseases and is superior to a traditional single-function method. According to the method, the release of the neutrophil NETs of the sheep is accurately regulated and controlled in a mode of combining pretreatment of the inhibitor and stimulation of the giardia trophozoite, and a new strategy is provided for prevention and treatment of diseases of the sheep.

The present invention refers to inhibitors of the S100 calcium- binding protein A9 (S100A9) / S100A8 – Toll Like Receptor 4(TLR4) dimer-receptor axis for use in the treatment of Heart Failure with preserved Ejection Fraction (HFpEF). The present invention further refers to pharmaceutical formulations comprising the said inhibitors. The present invention's use of compounds and pharmaceutical formulations may be advantageously employed in HFpEF by attenuating the deleterious effect on endothelial function and prevention of inflammation, production of reactive oxygen species, apoptosis, senescence and pro-fibrotic phenotype.

Disclosed herein are means, methods, and compositions of matter useful for stimulation of elastin / collagen production and suppression of matrix metalloprotease activity. The disclosure further provides compositionally useful preparations derived from regenerative cells that have been manipulated for optimum growth factor and anti-aging properties. In one embodiment cellular mixtures derived from regenerative cells contacted with activating signals. Said activating signals include stimulation of toll like receptors and other "danger" sensing molecules. In one embodiment regenerative factors are harvested from stem cells and compounded into composition preparations.

Therapeutic formulations and protocols for enhancement of hepatic regeneration, reduction / reversion of liver failure, and restoration of hepatic characteristics of young liver including augmented production of digestive enzymes, production of complement, and detoxificiation. In one embodiment endothelial progenitor cells are cultured in vitro under conditions capable of stimulating enhanced production of microvesicles such as exosomes and / or regenerative factors. Endothelial cells can be activated to produce regenerative factors and / or exosomes by exposure to toll like receptor agonists. Endothelial cells may be autologous, allogeneic or xenogeneic to the recipient.

A pharmaceutical combination and a use thereof. The pharmaceutical combination comprises a PD-1 inhibitor and / or a PD-L1 immune checkpoint inhibitor; and a Toll Like Receptor (TLR) agonist.